XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

BACKGROUND: Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of xentuzumab to everolimus and exemestane in patients with advanced breast cancer with...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Peter, Cortes, Javier, Joaquim, Ana, Jañez, Noelia Martínez, Morales, Serafín, Díaz-Redondo, Tamara, Blau, Sibel, Neven, Patrick, Lemieux, Julie, García-Sáenz, José Ángel, Hart, Lowell, Biyukov, Tsvetan, Baktash, Navid, Massey, Dan, Burris, Howard A., Rugo, Hope S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258741/
https://www.ncbi.nlm.nih.gov/pubmed/37308971
http://dx.doi.org/10.1186/s13058-023-01649-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258741/
https://www.ncbi.nlm.nih.gov/pubmed/37308971
http://dx.doi.org/10.1186/s13058-023-01649-w

Ejemplares similares